Navigation Links
Lentigen Corporation announces Sale of Lentiviral Vector Manufacturing Business and Change of Name to Opus Bio, Inc.
Date:8/14/2014

GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ -- Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been granted certain rights to deploy lentiviral technology in specified therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.  These rights include specified CAR T-cell based therapies as well as specified therapies for single-gene diseases and disorders.

Chimeric antigen receptor T cell therapy (CAR+ T) technologies have made significant advances during the past several years, as evidenced by consistent clinical results reported by several academic teams.  "We are pleased that Lentigen Corporation has been at the forefront of the lentiviral vector manufacturing innovation that has enabled these advances in the treatment of hematologic malignancies," said David Wetherell, Chairman of Lentigen Corporation.  He added, "this transaction will provide Opus Bio with ongoing access to innovations in lentiviral vector and cell processing technologies, while allowing the company to commit further resources toward the advancement its research and clinical development programs."

Opus Bio intends to make further announcements on the progress of its therapeutic pipeline during the coming months.

Opus Bio is a clinical-stage biotechnology company committed to developing potentially transformative cell therapies for cancer and single gene disorders. The company is backed by Biomark Capital, a life sciences and healthcare investment firm with offices in Greenwich, CT and San Francisco, CA.

Investor and media contact:
Douglas D. Lind, MD
Interim Chief Executive Officer
Opus Bio, Inc.
(203) 769-2348
doug@opusbio.com


'/>"/>
SOURCE Opus Bio, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Luminex Corporation to Present at JP Morgan Healthcare Conference
6. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
9. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
10. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
11. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... NEW YORK , February 4, 2016 ... (OTCQB: QBIO), a biotechnology acceleration company is pleased to provide ... --> --> Over the last 3 months ... note and securities purchase agreements exceeding $1,000,000. As a result, ... under our Mannin Research Inc. license agreement and expect that ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... (AI) and leading supplier of Semantic Graph Database technology has been recognized As ... Products ” by Corporate America Magazine. , “At Corporate America, it’s our priority ...
(Date:2/4/2016)... ... February 04, 2016 , ... Many of the engineers at FireflySci, Inc. have ... sets them apart from other cuvette manufacturers is their supercharged customer service and their ... top of this steady flow of inside information, they have recently revamped their manufacturing ...
Breaking Biology Technology:
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce the attainment of ... the result of the company,s laser focus on (and ... , it,s comprehensive, easy-to-use and highly affordable cloud-based technology ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):